#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1588	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2789	118.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1761	1761	C	220	C	156	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	1588	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2789	118.4	0	HET	.	.	.	C207T,A	.	207	207	C	784	784	C	143	C,T,A	97,20,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3140	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3817	167.8	0	.	n	.	0	T695C	SNP	695	695	T	1150	1150	C	213	C	157	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3140	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3817	167.8	0	.	n	.	0	A1638G	SNP	1638	1638	A	2093	2093	G	161	G,T	121,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3140	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3817	167.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2426	2426	C	212	C	155	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3140	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3817	167.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2500	2500	A	214	A	150	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3140	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3817	167.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3052	3052	C	218	C	157	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	108	folP	855	855	100.0	folP.l15.c4.ctg.1	1607	14.1	1	SNP	p	R229S	1	.	.	685	687	AGC	957	959	AGC	16;15;15	A;G;C	12;11;11	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	368	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3273	23.6	1	SNP	p	S91F	1	.	.	271	273	TTC	556	558	TTC	27;27;27	T;T;C	20;20;20	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	368	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3273	23.6	1	SNP	p	D95G	1	.	.	283	285	GGC	568	570	GGC	29;29;29	G;G;C	21;21;21	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	368	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3273	23.6	1	SNP	p	G95N	0	.	.	283	285	GGC	568	570	GGC	29;29;29	G;G;C	21;21;21	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	132	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1352	20.8	1	SNP	p	G45D	0	.	.	133	135	GGC	544	546	GGC	42;42;42	G;G;C	28;30;30	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	74	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	862	16.4	0	.	n	.	0	A197.	DEL	197	197	A	479	479	A	39	A	25	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	276	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2830	20.9	1	SNP	p	D86N	0	.	.	256	258	GAC	489	491	GAC	29;29;29	G;A;C	18;16;19	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	276	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2830	20.9	1	SNP	p	R87W	0	.	.	259	261	CGT	492	494	CGT	29;29;30	C;G;T	21;18;19	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	276	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2830	20.9	1	SNP	p	S87R	1	.	.	259	261	CGT	492	494	CGT	29;29;30	C;G;T	21;18;19	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	276	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2830	20.9	1	SNP	p	R87I	0	.	.	259	261	CGT	492	494	CGT	29;29;30	C;G;T	21;18;19	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	276	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2830	20.9	1	SNP	p	S88P	0	.	.	262	264	TCC	495	497	TCC	30;31;31	T;C;C	20;20;21	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	220	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3122	15.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	18;18;18	G;G;C	15;13;14	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1050	1052	GCC	48;49;49	G;C;C	34;34;34	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1053	1055	ATG	49;49;49	A;T;G	34;34;34	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1065	1067	ACC	48;48;48	A;C;C	33;33;33	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1065	1067	ACC	48;48;48	A;C;C	33;33;33	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1566	1568	ACC	34;34;33	A;C;C	25;25;26	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1620	1622	GCG	33;33;33	G;C;G	25;23;23	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1620	1622	GCG	33;33;33	G;C;G	25;23;23	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1743	1745	GGT	28;28;26	G;G,T;T	20;19,2;20	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1752	1754	AGC	20;20;20	A;G;C	14;13;13	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	290	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2098	27.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1770	1772	CCG	21;21;21	C,G;C,G;G,C	15,1;11,1;16,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	544	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3368	32.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1661	1663	CCG	25;25;25	C;C;G,T,C	18;20;14,1,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	126	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1908	13.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	451	451	C	7	C	5	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	196	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1712	22.5	0	.	p	.	0	Y211_A212insD	INS	631	631	T	996	996	T	49	T	33	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	196	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1712	22.5	1	SNP	p	G120K	1	.	.	358	360	AAG	723	725	AAG	26;26;26	A,C;A;G	18,1;19;19	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	196	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1712	22.5	1	SNP	p	A121N	1	.	.	361	363	AAC	726	728	AAC	26;26;26	A;A;C	19;19;19	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	196	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1712	22.5	1	SNP	p	N121D	0	.	.	361	363	AAC	726	728	AAC	26;26;26	A;A;C	19;19;19	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	826	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	5443	31.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	76	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1409	12.6	1	SNP	p	V57M	1	.	.	169	171	ATG	693	695	ATG	23;23;21	A;T;G	18;18;17	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
